Date published: 2026-7-6

1-800-457-3801

SCBT Portrait Logo
Seach Input

SLC25A33 CRISPR/Cas9 KO Plasmid (h): sc-413606

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: human
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • SLC25A33 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the SLC25A33 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    SLC25A33 CRISPR/Cas9 KO Plasmid (h)

    sc-413606
    20 µg
    $397.00

    Overview

    SLC25A33 encodes a mitochondrial inner membrane carrier implicated in transporting pyrimidine nucleotides required for intramitochondrial nucleic acid metabolism. By supporting mitochondrial DNA replication, transcription, and RNA turnover, SLC25A33 links nucleotide homeostasis to oxidative phosphorylation capacity and broader mitochondrial quality control processes. Altered mitochondrial nucleotide transport can perturb bioenergetics and elevate replication stress, connecting this carrier family to mechanisms relevant to neurodegeneration, metabolic dysfunction, and proliferative disease contexts. As a result, SLC25A33 is frequently studied in models of mitochondrial maintenance, redox balance, and stress-adaptive signaling.

    SLC25A33 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the SLC25A33 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the SLC25A33 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the SLC25A33 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish SLC25A33 protein expression.

    This CRISPR knockout system enables efficient generation of SLC25A33-deficient cell models for investigation of SLC25A33 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting SLC25A33 exon(s) critical for SLC25A33 function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple SLC25A33 genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by SLC25A33 CRISPR/Cas9 KO Plasmid (h) and SLC25A33 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the SLC25A33 locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by SLC25A33 HDR Plasmid (h) and SLC25A33 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by SLC25A33 homology arms to support homology-directed repair at defined SLC25A33 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.